NASDAQ:ERAS

Erasca Stock Insider Trading

Healthcare > Biotechnology

Buy ERAS

*Your capital is at risk

$18.15

-0.530 (-2.84%)

At Close: Jul 31, 2026

Erasca Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 41.46. In total, the insiders bought 26.02M and sold 232.4K ERAS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	41.46
● Buy	26.02M shares
● Sell	232.4K shares
95% Buy Activity Weak Negative Correlation
Sell Signal Low Confidence Apr 01, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 41.46. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Varney Michael David Director	Director	120 000 Value: $174.0K
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Casdin Alexander W. Director	Director	120 000 Value: $174.0K
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Bristol James Arthur Director	Director	120 000 Value: $174.0K
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Multani Pratik S Director	Director	120 000 Value: $174.0K
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Start Valerie Denise Harding Director	Director	120 000 Value: $174.0K
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Hambleton Julie Director	Director	120 000 Value: $174.0K
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Liu Jean I Director	Director	120 000 Value: $174.0K
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Varney Michael David Director	Director	120 000 Value: $174.0K
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Liu Jean I Director	Director	120 000 Value: $174.0K
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Hambleton Julie Director	Director	120 000 Value: $174.0K
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Start Valerie Denise Harding Director	Director	120 000 Value: $174.0K
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Multani Pratik S Director	Director	120 000 Value: $174.0K
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Bristol James Arthur Director	Director	120 000 Value: $174.0K
Jun 24, 2025 Buy	Stock option (right to buy) A-Award	Casdin Alexander W. Director	Director	120 000 Value: $174.0K
May 23, 2025 Buy	Common Stock G-Gift	Multani Pratik S Director	Director	6 200 Value: $8K
May 23, 2025 Sell	Common Stock G-Gift	Multani Pratik S Director	Director	6 200 Value: $0
May 23, 2025 Sell	Common Stock G-Gift	Multani Pratik S Director	Director	6 200 Value: $0
May 23, 2025 Buy	Common Stock G-Gift	Multani Pratik S Director	Director	6 200 Value: $8K
Mar 04, 2025 Buy	Stock Option (right to buy) M-Exempt	Morris Shannon Chief Medical Officer	Officer	20 000 Value: $34.0K
Feb 13, 2025 Buy	Stock option (right to buy) A-Award	Garner Ebun General Counsel & Corp. Sec.	Officer	50 000 Value: $81.5K
Feb 13, 2025 Buy	Stock option (right to buy) A-Award	Garner Ebun General Counsel & Corp. Sec.	Officer	50 000 Value: $81.5K
Feb 03, 2025 Buy	Stock option (right to buy) A-Award	Chacko David M. CFO And Cbo	C-Suite Officer	800 000 Value: $1.41M
Feb 03, 2025 Buy	Stock option (right to buy) A-Award	Morris Shannon Chief Medical Officer	Officer	780 000 Value: $1.37M
Feb 03, 2025 Buy	Stock option (right to buy) A-Award	Chacko David M. CFO And Cbo	C-Suite Officer	800 000 Value: $1.41M
Feb 03, 2025 Buy	Stock option (right to buy) A-Award	Morris Shannon Chief Medical Officer	Officer	780 000 Value: $1.37M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ERASCA, INC.

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also ...

Read Full Profile Here